MAAT INDEX

CLAIM #39101 · McDonald’s Corporation (MCD) · 2024Q1 earnings call · Apr 30, 2024 · due Dec 31, 2024

Maybe just to build, Eric, to what Chris said, I mean, the food and paper low single digits.

Ian Borden · CFO

PENDING
graded after results covering Dec 31, 2024 are reported

In context

on is focused on the U.S. because obviously I could give a different answer depending on where you are in the world. But if I focus just on the U.S., most of the pricing that you see now in the U.S. is carryover pricing. It's not new pricing per se. Most of it again is carryover pricing. That said, we do continue to see there's certainly labor inflation. Much of that is coming out of what happened in California. And on a national level, you could probably see we're expecting high single-digit labor inflation. Again, much of that from the bleed over of what California introduced. And then on food and paper inflation, I think that's gone down to much more historical levels. So we're back at more historical levels on what we see from a food and paper inflation going forward. Ian Borden: Maybe just to build, Eric, to what Chris said, I mean, the food and paper low single digits. So I think we have seen kind of favorable movement in this year, although we've still got a fair bit of carryover effect from '23 inflation, certainly into the first part of '24 from both food and paper and labor. I think what's important to note on pricing is, I think, our business, including our owner/operators, understand that the consumer is price-weary. And I think we certainly are going to be prudent and thoughtful about any further price increases that we're looking at for the rest of 2024 on that backdrop and keep working on the opportunity that we've talked about a fair bit already on the affordability and getting that in place to kind of address the consumer need. Mike Cieplak: Our next question is from Sara Senatore with Bank of America. Sara Senatore: I guess one clarifica

Verify independently

SEC filings for MCD · Claim quote is verbatim from the 2024Q1 earnings call.